Earnings Material +

Knight Therapeutics Reports First Quarter 2026 Results

Knight Therapeutics Q1 Earnings Beat Drives Guidance Hike Amidst LATAM Expansion

By The Northwire Desk — AI Analysis May 07, 2026 · 06:30 GUD · 7.51 KNIGHT THERAPEUTICS INC.

Executive Summary

Knight Therapeutics reported First Quarter 2026 results on May 7, 2026, announcing record-high revenues of $148.4 million, a 69% increase year-over-year.
Adjusted EBITDA reached $27.9 million (up 130% YoY), with Net Income rising to $13.2 million compared to $2.2 million in Q1 2025.
Full-year 2026 revenue guidance was increased to a range of $510 million to $525 million, up from the previous $490 million to $510 million range provided in March 2026.
The company ended Q1 with over $125 million in cash and equivalents, while reducing its revolving credit facility balance by repaying $10 million (outstanding balance ~$58.6 million).
Operational highlights include the acquisition of a manufacturing facility in Argentina, return of Canadian rights for six non-core products ($21.5 million received), and share repurchases of 1.32 million shares at an average price of $6.22.
Regulatory progress includes approvals/launches for Minjuvi (Brazil, Argentina), Bapocil (Colombia), Pemazyre (Argentina), and Akynzeo (Paraguay). A Health Canada submission for Qelbree was withdrawn due to partner manufacturing changes.

Material Impact

The news is classified as Material - Positive because the revenue growth of 69% YoY significantly exceeds typical quarterly expectations, and the guidance raise confirms sustained momentum beyond the initial FY2025 outlook.
Net Income tripled year-over-year ($13.2M vs $2.2M), indicating improved operational leverage and margin expansion (Gross Margin increased from 40% to 47%).
The increase in full-year guidance ($510-$525M) suggests management confidence that the Q1 run rate is sustainable or will be complemented by other quarters, despite Q1 being a strong start.
Cash position improvement (Net Cash >$66 million after debt repayment) reduces immediate dilution risk and provides flexibility for further M&A or R&D without urgent capital raises.
The acquisition of an Argentine manufacturing facility represents vertical integration, potentially lowering COGS and securing supply chains in key LATAM markets, which is a strategic positive not fully priced into previous guidance.

GUD · Price

Company Overview

Company Overview: Knight Therapeutics is a specialty pharmaceutical company focused on commercializing innovative products in Canada and Latin America. The business model relies on licensing, acquiring, and launching branded generics and specialty drugs.
Flagship Projects/Products:
- Minjuvi (tafasitamab): Oncology product for lymphoma; key growth driver with approvals in Brazil, Argentina, Mexico.
- Paladin Portfolio: Acquired June 2025, contributing significantly to Q1 revenue and expanding Canadian infrastructure.
- Sumitomo Assets: Includes Orgovyx (prostate cancer) and Myfembree (women's health), licensed for Canada/LATAM.
- Niktimvo (axatilimab): Chronic GVHD treatment, recently submitted in Brazil.
Development Stage: Commercial stage with multiple products launched or in late-stage regulatory review across LATAM markets.

More from KNIGHT THERAPEUTICS INC.